Dr. Sean Zeng is Senior Manager, Cross-sector Innovation Collaboration at Merck Innovation Hub China. He is responsible for technology foresight and scouting for Merck Innovation Fields including Liquid Biopsy Technologies. Before joining Merck, Dr. Zeng worked at GSK and J&J China R&D with business development and external alliance roles. He holds a bachelor's degree in Biotechnology from Peking University and a PhD degree in Neuroscience from Chinese Academy of Sciences.

Dr. Shichun Tu is CEO of Huidu (Shanghai) Medical Sciences and holds a Ph.D. from T.H. Morgan School of Biological Sciences, University of Kentucky, has served as assistant professor at Sanford Burnham Medical Research Institute, Adjunct Professor at Scintillon Institute, Senior Scientist and Director of Neural Degeneration Department at Allele Biotechnology, and CTO & Director of Medical & R&D at Shanghai RightOn Biotechnology. Dr. Tu received the research fund issued by NIH of the National Health Ministry four times. The research has been published in international professional journals such as Nature, Neuron and PNAS.

Dr. Qihui Shi is a professor of Fudan University Shanghai Medical College since summer of 2018. Before joining faculty of Fudan University, Dr. Shi is a professor of Shanghai Center for Systems Biomedicine at Shanghai Jiao Tong University from September 2011 to June 2018. Dr. Shi received his B.S. from Fudan University and a Ph.D. in Chemistry from University of California, Santa Barbara. Dr. Shi conducted his postdoc research at Caltech. His research interests are centered on developing new technologies in cell-based liquid biopsy.

曾思禹博士现在默克中国创新中心担任跨领域创新合作高级经理。他负责在包括液体活检领域在内的默克创新领域作技术前瞻和项目搜寻。在加入默克之前，曾博士先后在葛兰素史克和强生中国研发中心担任业务发展和外部联络职位。他拥有北京大学生物技术学士和中科院神经科学博士学位。

涂士春博士现任慧渡（上海）医疗科技有限公司CEO。涂士春博士毕业于美国肯塔基大学生物系，在美国Sanford Burnham Medical Research Institute、Scintillon Institute、美国Allele生物技术医药有限公司和上海睿昂生物技术有限公司先后担任助理教授、客座教授、疾病研究部主任、医学研发总监和首席技术官。涂士春博士四次获得美国国家卫生部NIH颁发的研究基金，科研成果发表在Nature, Neuron, PNAS等国际专业杂志。

施奇惠博士是复旦大学上海医学院生物医学研究院教授，此前他从2011年9月至2018年6月在上海交通大学系统生物医学研究院任教授。施博士在复旦大学获学士学位，在加州大学圣巴巴拉分校获化学博士学位，并在加州理工学院从事博士后研究。他的主要研究方向是发展基于细胞的液体活检新技术。